Averell Carlyne M, Hinds David, Fairburn-Beech Jolyon, Wu Benjamin, Lima Robson
US Value Evidence & Outcomes, GSK, Research Triangle Park, NC, USA.
Real World Evidence & Epidemiology, GSK, Collegeville, PA, USA.
J Asthma Allergy. 2021 Jul 1;14:755-771. doi: 10.2147/JAA.S291774. eCollection 2021.
The National Heart, Lung, and Blood Institute (NHLBI) recommend a stepwise approach to asthma management, with the goals of maintaining asthma control and reducing exacerbations. Although asthma treatments reduce the frequency of exacerbations, they still occur. We aimed to characterize the treated United States of America (US) adult asthma population, including those experiencing exacerbations, in terms of socio-demographics, clinical characteristics, and healthcare resource utilization (HRU).
A retrospective cohort of asthma patients aged ≥18 years on 01 January 2014 with ≥1 ICD-9 asthma code (493.xx) enrolled in a US healthcare claims database during 2013-2014. Patients who had ≥2 asthma medication dispensings during 2013 (baseline), including ≥1 in the 90-day period before index date, were classified according to NHLBI step. Patients with chronic obstructive pulmonary disease, cystic fibrosis, or lung cancer diagnoses were excluded. Demographics, comorbidities, clinical characteristics, and HRU were described during baseline. Exacerbations and HRU were described during 2014 (follow-up period).
In total, 72,156 patients were included; 10,590 (14.7%) had ≥1 exacerbation during follow-up. Approximately 44% of patients were classified as NHLBI Steps 1-2, 41% as Steps 3-4, and 11% as Steps 5-6. Exacerbation frequency increased with step (Steps 1, 2, and 3: 12-14%; Steps 4, 5, and 6: 16-26%). Compared with the overall population during baseline, patients with an exacerbation had similar demographics, but differences were observed for comorbid allergic rhinitis (46.4% vs 40.1%, respectively), blood eosinophil counts ≥300 cells/μL (45.5% vs 39.6%, respectively), and asthma-related healthcare encounters (62.9% vs 52.4%, respectively). Overall, asthma-related HRU during follow-up increased with NHLBI step.
Exacerbations were observed among patients classified at each NHLBI step and were more frequent with increasing step. Exacerbations and asthma-related HRU highlight the continued unmet need in the treated US asthma population.
美国国立心肺血液研究所(NHLBI)推荐采用逐步治疗法来管理哮喘,目标是维持哮喘控制并减少病情加重。尽管哮喘治疗可降低病情加重的频率,但病情仍会发作。我们旨在从社会人口统计学、临床特征和医疗资源利用(HRU)方面,对接受治疗的美国成年哮喘患者群体进行特征描述,包括那些病情发作的患者。
对2014年1月1日年龄≥18岁、在2013 - 2014年期间纳入美国医疗理赔数据库且有≥1个国际疾病分类第九版(ICD - 9)哮喘编码(493.xx)的哮喘患者进行回顾性队列研究。在2013年(基线期)有≥2次哮喘药物配药记录(包括在索引日期前90天内有≥1次配药记录)的患者,根据NHLBI分级进行分类。排除患有慢性阻塞性肺疾病、囊性纤维化或肺癌诊断的患者。在基线期描述人口统计学、合并症、临床特征和HRU情况。在2014年(随访期)描述病情加重情况和HRU情况。
总共纳入72156例患者;10590例(14.7%)在随访期间有≥1次病情加重。约44%的患者被分类为NHLBI 1 - 2级,41%为3 - 4级,11%为5 - 6级。病情加重频率随分级增加而升高(1 - 3级:12% - 14%;4 - 6级:16% - 26%)。与基线期的总体人群相比,病情加重的患者在人口统计学方面相似,但在合并过敏性鼻炎(分别为46.4%和40.1%)、血液嗜酸性粒细胞计数≥300个细胞/微升(分别为45.5%和39.6%)以及与哮喘相关的医疗接触(分别为62.9%和52.4%)方面存在差异。总体而言,随访期间与哮喘相关的HRU随NHLBI分级增加而升高。
在NHLBI每个分级的患者中均观察到病情加重情况,且随着分级增加病情加重更频繁。病情加重情况和与哮喘相关的HRU凸显了美国接受治疗的哮喘患者群体中持续未得到满足的需求。